SI9200143B - Method and composition for the prevention of lyme disease - Google Patents

Method and composition for the prevention of lyme disease Download PDF

Info

Publication number
SI9200143B
SI9200143B SI9200143A SI9200143A SI9200143B SI 9200143 B SI9200143 B SI 9200143B SI 9200143 A SI9200143 A SI 9200143A SI 9200143 A SI9200143 A SI 9200143A SI 9200143 B SI9200143 B SI 9200143B
Authority
SI
Slovenia
Prior art keywords
vaccine according
polypeptide
prevention
composition
immunogen
Prior art date
Application number
SI9200143A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9200143A (en
Inventor
Ian Livey
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9200143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of SI9200143A publication Critical patent/SI9200143A/sl
Publication of SI9200143B publication Critical patent/SI9200143B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9200143A 1991-07-11 1992-07-10 Method and composition for the prevention of lyme disease SI9200143B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72724591A 1991-07-11 1991-07-11
US82416192A 1992-01-22 1992-01-22
US07/903,580 US6221363B1 (en) 1991-07-11 1992-06-25 Vaccine for the prevention of lyme disease

Publications (2)

Publication Number Publication Date
SI9200143A SI9200143A (en) 1993-03-31
SI9200143B true SI9200143B (en) 2001-06-30

Family

ID=27419096

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9200143A SI9200143B (en) 1991-07-11 1992-07-10 Method and composition for the prevention of lyme disease

Country Status (17)

Country Link
US (2) US6221363B1 (fr)
EP (1) EP0522560B2 (fr)
JP (1) JP2611095B2 (fr)
AT (1) ATE198489T1 (fr)
AU (1) AU660178B2 (fr)
CA (1) CA2073486C (fr)
CZ (1) CZ280743B6 (fr)
DE (1) DE69231619T3 (fr)
DK (1) DK0522560T4 (fr)
ES (1) ES2154633T3 (fr)
FI (1) FI107334B (fr)
HR (1) HRP950174B1 (fr)
HU (1) HU219772B (fr)
MX (1) MX9204078A (fr)
NO (1) NO304546B1 (fr)
SI (1) SI9200143B (fr)
SK (1) SK217292A3 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
EP0701612B1 (fr) * 1993-04-29 1998-01-21 IMMUNO Aktiengesellschaft FORMULATION IMMUNOGENE DE VACCINS A BASE D'ANTIGENES OspC, DESTINEE A LA PREVENTION ET AU TRAITEMENT DE LA MALADIE DE LYME ET PROCEDES DE RECOMBINAISON POUR LA PREPARATION DE CES ANTIGENES
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995027504A1 (fr) 1994-04-11 1995-10-19 Solvay Animal Health, Inc. BACTERINE DE $i(BORRELIA BURGDORFERI)
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU712213B2 (en) * 1995-09-22 1999-11-04 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
EP0880543A4 (fr) * 1995-10-26 2000-08-02 Rhode Island Education Antigenes servant de candidats vaccins et tires du spirochete (borrelia burgdorferi) de la maladie de lyme induit par la salive d'une tique vecteur (ixodes scapularis)
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6667038B1 (en) * 1999-04-21 2003-12-23 Boston Medical Center Corp. Prevention, diagnosis and treatment of lyme disease
US7060281B1 (en) 1999-06-18 2006-06-13 Research Foundation Of The State University Of New York Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
ES2298249T3 (es) 2000-08-18 2008-05-16 Research Foundation Of State University Of New York Ospa modificada de borrelia burgdorferi.
US7442391B2 (en) 2002-01-25 2008-10-28 Integrated Botanical Technologies, Llc Bioactive botanical cosmetic compositions and processes for their production
US8277852B2 (en) 2002-01-25 2012-10-02 Akzo Nobel Surface Chemistry Llc Bioactive botanical cosmetic compositions and processes for their production
ES2465949T3 (es) 2004-01-12 2014-06-09 Akzo Nobel Surface Chemistry Llc Composiciones bioactivas de plantas de Theacea y procedimientos para su producción y uso
US8490650B2 (en) 2006-01-19 2013-07-23 Toyo Seikan Kaisha, Ltd. Coupler for transferring a liquid or other material between containers
MX2009004866A (es) 2006-11-03 2009-05-19 Schering Plough Ltd Vacuna para enfermedad de lyme canina.
AU2008217189B2 (en) * 2007-02-22 2013-06-13 Baxalta GmbH Method of purification of hydrophobic proteins
EP2274616A1 (fr) * 2008-04-22 2011-01-19 The Research Foundation of State University of New York Réseau de protéines d'enveloppes de cellules de borrelia burgdorferi
WO2011063003A2 (fr) * 2009-11-17 2011-05-26 Abaxis, Inc. Peptides et procédés pour la détection d'anticorps contre la maladie de lyme
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
KR102451333B1 (ko) * 2018-10-22 2022-10-06 주식회사 엘지화학 마이크로비드 및 그 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4767622A (en) * 1983-08-19 1988-08-30 University Of Illinois Method and materials for development of immunological responses protective against malarial infection
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
DE3818013A1 (de) 1988-05-27 1989-11-30 Henkel Kgaa Gewebeweichmachungsmittel
IT1223777B (it) * 1988-08-18 1990-09-29 Gevipi Ag Rubinetto a due uscite con inversore a depressione
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
ATE140461T1 (de) * 1989-12-22 1996-08-15 Mikrogen Molekularbiol Entw Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff
DE3942728C1 (en) 1989-12-22 1991-05-23 Mikrogen Molekularbiologische Entwicklungs-Gmbh, 8000 Muenchen, De New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections
WO1991013630A1 (fr) 1990-03-05 1991-09-19 The United States Of America, Represented By The Secretary, United States Department Of Commerce PROTEINES ANTIGENIQUES DE $i(BORRELIA BURGDORFERI)
EP1016416A3 (fr) * 1990-07-06 2002-10-23 Wyeth Vaccin contre la maladie de lyme et modèle pour l'évaluation de l'efficacité du vaccin

Also Published As

Publication number Publication date
JP2611095B2 (ja) 1997-05-21
CZ280743B6 (cs) 1996-04-17
HU219772B (hu) 2001-07-30
SK279250B6 (sk) 1998-08-05
HU9202289D0 (en) 1992-10-28
EP0522560B2 (fr) 2006-12-20
ATE198489T1 (de) 2001-01-15
NO922746D0 (no) 1992-07-10
NO304546B1 (no) 1999-01-11
AU1934992A (en) 1993-01-14
EP0522560B1 (fr) 2001-01-03
CA2073486C (fr) 2002-07-02
EP0522560A2 (fr) 1993-01-13
AU660178B2 (en) 1995-06-15
DK0522560T3 (da) 2001-03-05
HUT66525A (en) 1994-12-28
FI107334B (fi) 2001-07-13
DK0522560T4 (da) 2007-04-10
DE69231619T3 (de) 2007-07-12
DE69231619T2 (de) 2001-05-31
FI923175A (fi) 1993-01-12
SK217292A3 (en) 1998-08-05
DE69231619D1 (de) 2001-02-08
JPH072696A (ja) 1995-01-06
FI923175A0 (fi) 1992-07-09
SI9200143A (en) 1993-03-31
HRP950174B1 (en) 2001-08-31
MX9204078A (es) 1993-04-01
ES2154633T3 (es) 2001-04-16
US6221363B1 (en) 2001-04-24
US5530103A (en) 1996-06-25
HRP950174A2 (en) 1997-08-31
CZ217292A3 (en) 1993-01-13
NO922746L (no) 1993-01-12
CA2073486A1 (fr) 1993-01-12
EP0522560A3 (en) 1994-05-11

Similar Documents

Publication Publication Date Title
SI9200143B (en) Method and composition for the prevention of lyme disease
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
BRPI9609414B8 (pt) combinação de vacina e kit para produzir a mesma.
IL102639A (en) Compositions for inducing cytotoxic t lymphocyte responses
IL76777A (en) Inositoltriphosphates,their preparation and pharmaceutical compositions containing them
CA2218619A1 (fr) Compositions antibacteriennes cicatrisantes et leurs procedes de preparation et d'utilisation
ATE100484T1 (de) Lagerstabile aufhellerformulierung.
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
DK503687D0 (da) Farmaceutisk praeparat af ibuprofen
ES2183223T3 (es) Composicion para uso veterinario intramamaria que no contiene agentes antiinflamatorios.
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
CA2039194A1 (fr) Utilisations de l-deprenyl et de compositions qui en derivent
IL106968A0 (en) Potentiation of immunogenic response
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
ATA186692A (de) Pharmazeutische zusammensetzung
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
CA2049325A1 (fr) Peptide, composition immunogene et vaccin ou preparation medicinale; methode d'immunisation d'un mammifere contre lhrh et methode pour ameliorer la qualite de la viande de porc
ES2062292T3 (es) Un proceso para la preparacion del compuesto que tiene la estructura (7alfa,17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-in-3-ona.
ATE181505T1 (de) Phosphozucker enthaltende pharmazeutische zubereitung
CA2078605A1 (fr) Vaccin contre l'anemie infectieuse du poulet
RU93058633A (ru) Противоядие, способ его получения, фармацевтическая композиция, способ противодействия яду и комплект
EP0351876A3 (fr) Composition pour augmenter l'effet de vaccination
FI981624A (fi) Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelemiseksi
ES526556A0 (es) Procedimiento para la preparacion de nuevas piridobenzodiazepinonas

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20050408